Family-owned drug factories in India eroding US generic prices
Deep discounts offered by new Indian players to gain market share force incumbent players to match them
Add BT as a preferred sourcePublished Thu, Aug 31, 2017 · 09:50 PM
Mumbai
THE most recent earnings reports across the generic drug industry have read like dispatches from the front lines of a price war.
This month, the world's largest copycat drugmaker, Israel's Teva Pharmaceutical Industries Ltd, slashed its dividend; US giant Mylan NV lowered its profit target; and India's Sun Pharmaceutical Industries Ltd reported its first quarterly loss in at least 12 years.
